Net Cash Provided by (Used in) Financing Activities of Immunome Inc. from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Immunome Inc. annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
  • Immunome Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $162,228,000, a 26% decline year-over-year.
  • Immunome Inc. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $640,357,000, a 166% increase from 2024.
  • Immunome Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $240,529,000, a 107% increase from 2023.
  • Immunome Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $116,408,000, a 264% increase from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

Immunome Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $640,357,000 +$399,828,000 +166% 01 Jan 2025 31 Dec 2025 10-K 03 Mar 2026 2025 FY
2024 $240,529,000 +$124,121,000 +107% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2026 2025 FY
2023 $116,408,000 +$84,408,000 +264% 01 Jan 2023 31 Dec 2023 10-K 19 Mar 2025 2024 FY
2022 $32,000,000 +$4,232,000 +15% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $27,768,000 -$22,175,000 -44% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $49,943,000 +$39,169,000 +364% 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
2019 $10,774,000 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY

Immunome Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $162,228,000 -$57,217,000 -26% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q1 2024 $219,445,000 +$219,411,000 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q1 2023 $34,000* -$31,966,000 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q1 2022 $32,000,000 +$31,924,000 +42005% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q1 2021 $76,000 -$768,000 -91% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q1 2020 $844,000 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.